New drug TQB2102 vs standard therapy for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your breast cancer is HER2-positive and has come back or spread to other parts of the body.
- You have not had any chemotherapy or other cancer treatment for the spread of the disease (except for up to one type of hormone therapy).
- You have a tumor that can be measured on a scan.
- Your cancer has not spread to your brain or spinal cord, or if it has, it is well controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combinations of drugs given before surgery to shrink HER2-positive breast cancer. One uses a new experimental drug (TQB2102) and the other uses standard treatments. The goal is to see which works better at reducing the cancer before surgery.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
This trial tests an investigational drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to see how safe the drug is and how the body processes it, and it may offer a new option for those with few alternatives.
This study tests a new drug called TQB3126 for people with breast cancer that has gotten worse after previous treatments. The goal is to see if the drug is safe and helps shrink or slow the cancer.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.